JP2015124182A - Sebum synthesis promoter - Google Patents
Sebum synthesis promoter Download PDFInfo
- Publication number
- JP2015124182A JP2015124182A JP2013269695A JP2013269695A JP2015124182A JP 2015124182 A JP2015124182 A JP 2015124182A JP 2013269695 A JP2013269695 A JP 2013269695A JP 2013269695 A JP2013269695 A JP 2013269695A JP 2015124182 A JP2015124182 A JP 2015124182A
- Authority
- JP
- Japan
- Prior art keywords
- sebum
- extract
- skin
- sebaceous gland
- food
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000002374 sebum Anatomy 0.000 title claims abstract description 59
- 230000015572 biosynthetic process Effects 0.000 title claims abstract description 43
- 238000003786 synthesis reaction Methods 0.000 title claims abstract description 43
- 210000001732 sebaceous gland Anatomy 0.000 claims abstract description 53
- 239000000284 extract Substances 0.000 claims abstract description 49
- 235000013305 food Nutrition 0.000 claims abstract description 19
- 239000003814 drug Substances 0.000 claims abstract description 18
- 239000002537 cosmetic Substances 0.000 claims abstract description 14
- 229940079593 drug Drugs 0.000 claims abstract description 13
- 239000004480 active ingredient Substances 0.000 claims abstract description 10
- 239000000203 mixture Substances 0.000 claims description 63
- 230000004069 differentiation Effects 0.000 claims description 19
- 230000001737 promoting effect Effects 0.000 claims description 16
- 241000238017 Astacoidea Species 0.000 claims description 12
- 239000003795 chemical substances by application Substances 0.000 claims description 11
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 4
- 229940127557 pharmaceutical product Drugs 0.000 claims description 4
- 235000015872 dietary supplement Nutrition 0.000 claims description 3
- 235000013376 functional food Nutrition 0.000 claims description 3
- 230000036541 health Effects 0.000 claims description 3
- 235000013402 health food Nutrition 0.000 claims description 3
- 230000007812 deficiency Effects 0.000 abstract description 6
- 210000004761 scalp Anatomy 0.000 abstract description 6
- 241000123835 Ampelopsis japonica Species 0.000 abstract description 3
- 230000002085 persistent effect Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 55
- 238000009472 formulation Methods 0.000 description 37
- 239000000047 product Substances 0.000 description 28
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 27
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 27
- 239000004615 ingredient Substances 0.000 description 21
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 20
- 230000000694 effects Effects 0.000 description 19
- 239000003921 oil Substances 0.000 description 19
- 235000019198 oils Nutrition 0.000 description 18
- 239000008213 purified water Substances 0.000 description 18
- 241000196324 Embryophyta Species 0.000 description 14
- 241000237502 Ostreidae Species 0.000 description 14
- 235000020636 oyster Nutrition 0.000 description 14
- 239000012071 phase Substances 0.000 description 14
- 239000008346 aqueous phase Substances 0.000 description 13
- 238000004519 manufacturing process Methods 0.000 description 13
- -1 vacuum concentration Substances 0.000 description 13
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 12
- 238000002360 preparation method Methods 0.000 description 12
- 238000010438 heat treatment Methods 0.000 description 11
- 235000011187 glycerol Nutrition 0.000 description 10
- 230000028327 secretion Effects 0.000 description 10
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- 239000003205 fragrance Substances 0.000 description 9
- 239000007788 liquid Substances 0.000 description 9
- 238000003756 stirring Methods 0.000 description 9
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 8
- 239000000654 additive Substances 0.000 description 8
- 239000006071 cream Substances 0.000 description 8
- 239000000469 ethanolic extract Substances 0.000 description 8
- 230000014509 gene expression Effects 0.000 description 8
- 239000006210 lotion Substances 0.000 description 8
- 238000002156 mixing Methods 0.000 description 8
- 239000002304 perfume Substances 0.000 description 8
- 239000003755 preservative agent Substances 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 7
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 7
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 7
- 150000002632 lipids Chemical class 0.000 description 7
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 7
- 239000002674 ointment Substances 0.000 description 7
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
- 235000013361 beverage Nutrition 0.000 description 6
- 229960000541 cetyl alcohol Drugs 0.000 description 6
- 239000000839 emulsion Substances 0.000 description 6
- 238000000605 extraction Methods 0.000 description 6
- 239000000706 filtrate Substances 0.000 description 6
- 239000000499 gel Substances 0.000 description 6
- 235000021355 Stearic acid Nutrition 0.000 description 5
- 239000004359 castor oil Substances 0.000 description 5
- 235000019438 castor oil Nutrition 0.000 description 5
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 5
- 230000006698 induction Effects 0.000 description 5
- 229940057995 liquid paraffin Drugs 0.000 description 5
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 5
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 230000002441 reversible effect Effects 0.000 description 5
- 239000008117 stearic acid Substances 0.000 description 5
- 229940058015 1,3-butylene glycol Drugs 0.000 description 4
- 241000699800 Cricetinae Species 0.000 description 4
- 206010013786 Dry skin Diseases 0.000 description 4
- 235000019437 butane-1,3-diol Nutrition 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 230000002950 deficient Effects 0.000 description 4
- 235000014113 dietary fatty acids Nutrition 0.000 description 4
- NOPFSRXAKWQILS-UHFFFAOYSA-N docosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCO NOPFSRXAKWQILS-UHFFFAOYSA-N 0.000 description 4
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 4
- 230000037336 dry skin Effects 0.000 description 4
- 239000000194 fatty acid Substances 0.000 description 4
- 229930195729 fatty acid Natural products 0.000 description 4
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 239000003960 organic solvent Substances 0.000 description 4
- 208000017520 skin disease Diseases 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 201000004624 Dermatitis Diseases 0.000 description 3
- 101150018889 FABP4 gene Proteins 0.000 description 3
- 101150112014 Gapdh gene Proteins 0.000 description 3
- 239000004166 Lanolin Substances 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 101150023417 PPARG gene Proteins 0.000 description 3
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 3
- 241000235527 Rhizopus Species 0.000 description 3
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000000996 additive effect Effects 0.000 description 3
- 208000010668 atopic eczema Diseases 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 3
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 235000019388 lanolin Nutrition 0.000 description 3
- 229940039717 lanolin Drugs 0.000 description 3
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 3
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 3
- 239000004006 olive oil Substances 0.000 description 3
- 235000008390 olive oil Nutrition 0.000 description 3
- 101150047829 plin-1 gene Proteins 0.000 description 3
- 230000002335 preservative effect Effects 0.000 description 3
- 239000002453 shampoo Substances 0.000 description 3
- 239000000344 soap Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 229940032094 squalane Drugs 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 2
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 2
- ASKIVFGGGGIGKH-UHFFFAOYSA-N 2,3-dihydroxypropyl 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCC(=O)OCC(O)CO ASKIVFGGGGIGKH-UHFFFAOYSA-N 0.000 description 2
- BGRXBNZMPMGLQI-UHFFFAOYSA-N 2-octyldodecyl tetradecanoate Chemical compound CCCCCCCCCCCCCC(=O)OCC(CCCCCCCC)CCCCCCCCCC BGRXBNZMPMGLQI-UHFFFAOYSA-N 0.000 description 2
- 208000002874 Acne Vulgaris Diseases 0.000 description 2
- 244000036975 Ambrosia artemisiifolia Species 0.000 description 2
- 235000003129 Ambrosia artemisiifolia var elatior Nutrition 0.000 description 2
- 244000025254 Cannabis sativa Species 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- 101100447432 Danio rerio gapdh-2 gene Proteins 0.000 description 2
- 235000001602 Digitaria X umfolozi Nutrition 0.000 description 2
- 235000017898 Digitaria ciliaris Nutrition 0.000 description 2
- 235000005476 Digitaria cruciata Nutrition 0.000 description 2
- 235000006830 Digitaria didactyla Nutrition 0.000 description 2
- 235000005804 Digitaria eriantha ssp. eriantha Nutrition 0.000 description 2
- 235000010823 Digitaria sanguinalis Nutrition 0.000 description 2
- 244000025670 Eleusine indica Species 0.000 description 2
- 235000014716 Eleusine indica Nutrition 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 2
- 239000005639 Lauric acid Substances 0.000 description 2
- 235000021314 Palmitic acid Nutrition 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 244000228451 Stevia rebaudiana Species 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 206010048218 Xeroderma Diseases 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 206010000496 acne Diseases 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 2
- 235000003484 annual ragweed Nutrition 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 230000003796 beauty Effects 0.000 description 2
- 235000013871 bee wax Nutrition 0.000 description 2
- 239000012166 beeswax Substances 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 235000006263 bur ragweed Nutrition 0.000 description 2
- 230000024245 cell differentiation Effects 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 235000003488 common ragweed Nutrition 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- UKMSUNONTOPOIO-UHFFFAOYSA-N docosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCCCC(O)=O UKMSUNONTOPOIO-UHFFFAOYSA-N 0.000 description 2
- 229960000735 docosanol Drugs 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 239000003349 gelling agent Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 206010021198 ichthyosis Diseases 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 229940119170 jojoba wax Drugs 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000001630 malic acid Substances 0.000 description 2
- 235000011090 malic acid Nutrition 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 2
- 229940073665 octyldodecyl myristate Drugs 0.000 description 2
- 235000014593 oils and fats Nutrition 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 235000009736 ragweed Nutrition 0.000 description 2
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 2
- 235000020637 scallop Nutrition 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000001593 sorbitan monooleate Substances 0.000 description 2
- 235000011069 sorbitan monooleate Nutrition 0.000 description 2
- 229940035049 sorbitan monooleate Drugs 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- HLZKNKRTKFSKGZ-UHFFFAOYSA-N tetradecan-1-ol Chemical compound CCCCCCCCCCCCCCO HLZKNKRTKFSKGZ-UHFFFAOYSA-N 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- DUXYWXYOBMKGIN-UHFFFAOYSA-N trimyristin Chemical compound CCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCC DUXYWXYOBMKGIN-UHFFFAOYSA-N 0.000 description 2
- 239000000230 xanthan gum Substances 0.000 description 2
- 235000010493 xanthan gum Nutrition 0.000 description 2
- 229920001285 xanthan gum Polymers 0.000 description 2
- 229940082509 xanthan gum Drugs 0.000 description 2
- LGQKSQQRKHFMLI-SJYYZXOBSA-N (2s,3r,4s,5r)-2-[(3r,4r,5r,6r)-4,5,6-trihydroxyoxan-3-yl]oxyoxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)CO[C@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)OC1 LGQKSQQRKHFMLI-SJYYZXOBSA-N 0.000 description 1
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
- ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 description 1
- FRPZMMHWLSIFAZ-UHFFFAOYSA-N 10-undecenoic acid Chemical compound OC(=O)CCCCCCCCC=C FRPZMMHWLSIFAZ-UHFFFAOYSA-N 0.000 description 1
- TWJNQYPJQDRXPH-UHFFFAOYSA-N 2-cyanobenzohydrazide Chemical compound NNC(=O)C1=CC=CC=C1C#N TWJNQYPJQDRXPH-UHFFFAOYSA-N 0.000 description 1
- LGQKSQQRKHFMLI-UHFFFAOYSA-N 4-O-beta-D-xylopyranosyl-beta-D-xylopyranose Natural products OC1C(O)C(O)COC1OC1C(O)C(O)C(O)OC1 LGQKSQQRKHFMLI-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 235000021357 Behenic acid Nutrition 0.000 description 1
- 235000007866 Chamaemelum nobile Nutrition 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- SQNRKWHRVIAKLP-UHFFFAOYSA-N D-xylobiose Natural products O=CC(O)C(O)C(CO)OC1OCC(O)C(O)C1O SQNRKWHRVIAKLP-UHFFFAOYSA-N 0.000 description 1
- 208000001840 Dandruff Diseases 0.000 description 1
- 206010012435 Dermatitis and eczema Diseases 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- 102000013948 Fatty acid-binding protein 4 Human genes 0.000 description 1
- 108050003772 Fatty acid-binding protein 4 Proteins 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 240000005926 Hamelia patens Species 0.000 description 1
- 206010020112 Hirsutism Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 244000042664 Matricaria chamomilla Species 0.000 description 1
- 235000007232 Matricaria chamomilla Nutrition 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 235000021360 Myristic acid Nutrition 0.000 description 1
- TUNFSRHWOTWDNC-UHFFFAOYSA-N Myristic acid Natural products CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 description 1
- AOMUHOFOVNGZAN-UHFFFAOYSA-N N,N-bis(2-hydroxyethyl)dodecanamide Chemical compound CCCCCCCCCCCC(=O)N(CCO)CCO AOMUHOFOVNGZAN-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
- GWFGDXZQZYMSMJ-UHFFFAOYSA-N Octadecansaeure-heptadecylester Natural products CCCCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCCCC GWFGDXZQZYMSMJ-UHFFFAOYSA-N 0.000 description 1
- 108010016731 PPAR gamma Proteins 0.000 description 1
- 235000019482 Palm oil Nutrition 0.000 description 1
- 241000237509 Patinopecten sp. Species 0.000 description 1
- 241000237503 Pectinidae Species 0.000 description 1
- 102100031261 Perilipin-1 Human genes 0.000 description 1
- 108010067162 Perilipin-1 Proteins 0.000 description 1
- 102000012132 Peroxisome proliferator-activated receptor gamma Human genes 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 108010009736 Protein Hydrolysates Proteins 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 206010040799 Skin atrophy Diseases 0.000 description 1
- 208000028990 Skin injury Diseases 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- BCKXLBQYZLBQEK-KVVVOXFISA-M Sodium oleate Chemical compound [Na+].CCCCCCCC\C=C/CCCCCCCC([O-])=O BCKXLBQYZLBQEK-KVVVOXFISA-M 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 208000033809 Suppuration Diseases 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 241000219094 Vitaceae Species 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 150000008051 alkyl sulfates Chemical class 0.000 description 1
- FYGDTMLNYKFZSV-DZOUCCHMSA-N alpha-D-Glcp-(1->4)-alpha-D-Glcp-(1->4)-D-Glcp Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)O[C@H](O[C@@H]2[C@H](OC(O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-DZOUCCHMSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 239000013040 bath agent Substances 0.000 description 1
- 239000003788 bath preparation Substances 0.000 description 1
- 229940116226 behenic acid Drugs 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- KHAVLLBUVKBTBG-UHFFFAOYSA-N caproleic acid Natural products OC(=O)CCCCCCCC=C KHAVLLBUVKBTBG-UHFFFAOYSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 229940084030 carboxymethylcellulose calcium Drugs 0.000 description 1
- 239000004203 carnauba wax Substances 0.000 description 1
- 235000013869 carnauba wax Nutrition 0.000 description 1
- 229960001777 castor oil Drugs 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 229940082500 cetostearyl alcohol Drugs 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 235000021557 concentrated beverage Nutrition 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- DTPCFIHYWYONMD-UHFFFAOYSA-N decaethylene glycol Polymers OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO DTPCFIHYWYONMD-UHFFFAOYSA-N 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001877 deodorizing effect Effects 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 235000021186 dishes Nutrition 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 229960001484 edetic acid Drugs 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 238000012869 ethanol precipitation Methods 0.000 description 1
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 235000008524 evening primrose extract Nutrition 0.000 description 1
- 239000010475 evening primrose oil Substances 0.000 description 1
- 229940089020 evening primrose oil Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- FODTZLFLDFKIQH-FSVGXZBPSA-N gamma-Oryzanol (TN) Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)O[C@@H]2C([C@@H]3CC[C@H]4[C@]5(C)CC[C@@H]([C@@]5(C)CC[C@@]54C[C@@]53CC2)[C@H](C)CCC=C(C)C)(C)C)=C1 FODTZLFLDFKIQH-FSVGXZBPSA-N 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 229940074052 glyceryl isostearate Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 235000021021 grapes Nutrition 0.000 description 1
- 230000003700 hair damage Effects 0.000 description 1
- 208000024963 hair loss Diseases 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 239000008269 hand cream Substances 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- DWMMZQMXUWUJME-UHFFFAOYSA-N hexadecyl octanoate Chemical compound CCCCCCCCCCCCCCCCOC(=O)CCCCCCC DWMMZQMXUWUJME-UHFFFAOYSA-N 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229940031957 lauric acid diethanolamide Drugs 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000002932 luster Substances 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 235000020124 milk-based beverage Nutrition 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 229940043348 myristyl alcohol Drugs 0.000 description 1
- 229950006780 n-acetylglucosamine Drugs 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- NKBWPOSQERPBFI-UHFFFAOYSA-N octadecyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCCCC NKBWPOSQERPBFI-UHFFFAOYSA-N 0.000 description 1
- IIGMITQLXAGZTL-UHFFFAOYSA-N octyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCC IIGMITQLXAGZTL-UHFFFAOYSA-N 0.000 description 1
- 229940055577 oleyl alcohol Drugs 0.000 description 1
- XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 235000019629 palatability Nutrition 0.000 description 1
- 239000002540 palm oil Substances 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000003531 protein hydrolysate Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 238000010807 real-time PCR kit Methods 0.000 description 1
- 235000021067 refined food Nutrition 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000007127 saponification reaction Methods 0.000 description 1
- 239000003352 sequestering agent Substances 0.000 description 1
- 230000021148 sequestering of metal ion Effects 0.000 description 1
- 230000037380 skin damage Effects 0.000 description 1
- 230000008491 skin homeostasis Effects 0.000 description 1
- 230000005808 skin problem Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- BTURAGWYSMTVOW-UHFFFAOYSA-M sodium dodecanoate Chemical compound [Na+].CCCCCCCCCCCC([O-])=O BTURAGWYSMTVOW-UHFFFAOYSA-M 0.000 description 1
- 229940082004 sodium laurate Drugs 0.000 description 1
- 229940045845 sodium myristate Drugs 0.000 description 1
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
- 229940045870 sodium palmitate Drugs 0.000 description 1
- 229940080350 sodium stearate Drugs 0.000 description 1
- GGXKEBACDBNFAF-UHFFFAOYSA-M sodium;hexadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCC([O-])=O GGXKEBACDBNFAF-UHFFFAOYSA-M 0.000 description 1
- JUQGWKYSEXPRGL-UHFFFAOYSA-M sodium;tetradecanoate Chemical compound [Na+].CCCCCCCCCCCCCC([O-])=O JUQGWKYSEXPRGL-UHFFFAOYSA-M 0.000 description 1
- 235000014214 soft drink Nutrition 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 229940031439 squalene Drugs 0.000 description 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 229940012831 stearyl alcohol Drugs 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- TUNFSRHWOTWDNC-HKGQFRNVSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCC[14C](O)=O TUNFSRHWOTWDNC-HKGQFRNVSA-N 0.000 description 1
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 1
- 230000003813 thin hair Effects 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 1
- 229940042585 tocopherol acetate Drugs 0.000 description 1
- 235000015961 tonic Nutrition 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 229960000716 tonics Drugs 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- VLPFTAMPNXLGLX-UHFFFAOYSA-N trioctanoin Chemical compound CCCCCCCC(=O)OCC(OC(=O)CCCCCCC)COC(=O)CCCCCCC VLPFTAMPNXLGLX-UHFFFAOYSA-N 0.000 description 1
- 229960002703 undecylenic acid Drugs 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 150000003712 vitamin E derivatives Chemical class 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
Landscapes
- Cosmetics (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Non-Alcoholic Beverages (AREA)
Abstract
Description
本発明は、カガミグサの抽出物を有効成分として含有する皮脂合成促進剤、ならびに該皮脂合成促進剤を含む医薬品、医薬部外品、化粧品及び飲食品などの各種組成物に関する。 TECHNICAL FIELD The present invention relates to a sebum synthesis accelerator containing an extract of Rhizopus as an active ingredient, and various compositions such as pharmaceuticals, quasi-drugs, cosmetics and foods and drinks containing the sebum synthesis accelerator.
皮脂は、皮脂腺で皮脂腺細胞により合成され、皮膚表面に分泌される。分泌された皮脂は、皮膚を覆うことで体内からの水分の蒸発を防ぐとともに、外部からの物理的・化学的刺激、あるいは病原性の強い細菌・カビなどの侵入を防ぐなど、重要な機能を果している。このため、皮膚において皮脂の分泌が欠乏すると乾燥肌や座瘡等の皮膚トラブル及び皮脂欠乏性皮膚炎・湿疹(乾皮症)などの様々な皮膚疾患の原因となる（非特許文献１、２）。また、皮脂は、毛髪に対して必要かつ適度の油分を供給する働きもあり、毛髪のしなやかさや美しさを保つ上で有効な成分である。 Sebum is synthesized by sebaceous gland cells in the sebaceous glands and secreted to the skin surface. Secreted sebum prevents the evaporation of moisture from the body by covering the skin, and has important functions such as physical and chemical stimulation from the outside, and the invasion of highly pathogenic bacteria and molds. It's done. For this reason, lack of sebum secretion in the skin causes skin problems such as dry skin and acne and various skin diseases such as sebum-deficient dermatitis and eczema (xeroderma) (Non-Patent Documents 1 and 2). ). Sebum also has a function of supplying necessary and appropriate oil to the hair, and is an effective component for maintaining the suppleness and beauty of hair.
皮脂は、上記のとおり、皮膚や髪のうるおいを保つ上で重要であるが、その合成は年齢と共に衰える。これは、加齢による皮脂腺の萎縮と皮脂合成能の低下によるものと考えられている（非特許文献３、４）。このような皮脂分泌機能の衰えた皮膚に対してはクリーム、ローション、乳液等の医薬品、医薬部外品及び化粧品により油分の補給が行われている。しかし、これらの油分の補給用の製品は、皮膚表面に一時的に滞留はするものの、その効果は一過性のもので、持続した効果及び根本的な改善には至っていない。また強いステロイド外用薬も効果はあるものの、長期使用によって、皮膚萎縮、毛細血管拡張、色素斑などの様々な副作用が生じるという問題がある。 As described above, sebum is important for maintaining the moisture of skin and hair, but its synthesis declines with age. This is believed to be due to sebaceous gland atrophy and a decrease in sebum synthesis ability due to aging (Non-Patent Documents 3 and 4). Such skin with a reduced sebum secretion function is supplemented with oils by drugs such as creams, lotions and emulsions, quasi-drugs and cosmetics. However, these oil replenishment products temporarily stay on the skin surface, but their effects are temporary and have not led to sustained effects and fundamental improvements. In addition, although strong topical steroid drugs are effective, there are problems that various side effects such as skin atrophy, capillary vasodilation, and pigmentation are caused by long-term use.
これまで、皮脂腺細胞を直接賦活化することによって皮脂の合成および分泌を促す作用を有する成分として、例えば、γ−オリザノール（非特許文献５）、ウンデシレン酸（特許文献１）、マルトオリゴ糖（特許文献２）、ビタミンＥ誘導体（特許文献３）、シクレアニン抽出物（特許文献４）などが知られており、これらの有効成分を用いることで、皮脂分泌を促し、肌の乾燥やざ瘡などの発生を抑え、皮膚の恒常性維持に効果を発揮すると報告されている。しかし、その効果は満足いくものではなく、さらに持続性のある皮脂合成・分泌促進剤および皮膚保湿剤の開発が望まれている。 Until now, as a component having an action of promoting the synthesis and secretion of sebum by directly activating sebaceous gland cells, for example, γ-oryzanol (Non-patent Document 5), undecylenic acid (Patent Document 1), maltooligosaccharide (Patent Document) 2) Vitamin E derivatives (Patent Document 3), citranenin extract (Patent Document 4), etc. are known. By using these active ingredients, sebum secretion is promoted, and dry skin and acne occur. It has been reported to exert an effect on maintaining skin homeostasis. However, the effect is not satisfactory, and further development of a sebum synthesis / secretion promoter and a skin moisturizer is desired.
これまでの研究により、皮脂腺細胞は、その前駆細胞(皮脂腺未分化細胞)が分化することで生み出され、さらに皮脂腺細胞で合成された皮脂は皮脂腺細胞が破裂することで分泌されることが知られている（非特許文献６）。そのため皮脂の分泌を根本的に調節するためには、分化成熟した皮脂腺細胞の皮脂合成・分泌を制御するだけでなく、皮脂腺未分化細胞からはじまる分化過程を適切に制御する必要がある。 Based on previous studies, it is known that sebaceous gland cells are produced by the differentiation of their progenitor cells (sebaceous gland undifferentiated cells), and sebum synthesized by sebaceous gland cells is secreted by sebaceous gland cell rupture. (Non-Patent Document 6). Therefore, in order to fundamentally regulate sebum secretion, it is necessary not only to control sebum synthesis / secretion of differentiated and sebaceous gland cells, but also to appropriately control the differentiation process starting from sebaceous gland undifferentiated cells.
カガミグサ（学名：Ampelopsis japonica）はブドウ科ブドウ属に属する蔓性多年草植物で、その塊状の根に解毒作用、解熱作用、鎮痛作用があることから皮膚の化膿や腫れもの治療用の漢方薬に用いられている。また、カガミグサは、コラーゲン架橋阻害作用や整肌作用も確認されている（特許文献５）。しかしながら、皮脂腺未分化細胞の皮脂腺細胞への分化促進効果や皮脂腺細胞による皮脂合成促進効果についてはこれまで何ら知られていない。 Kagamigusa (scientific name: Ampelopsis japonica) is a vine perennial plant belonging to the vine family Grapes, and its blocky roots have detoxification, antipyretic, and analgesic effects, and are used in Chinese medicine for the treatment of suppuration and swelling of the skin. ing. In addition, the crayfish has been confirmed to have a collagen crosslinking inhibitory action and skin conditioning action (Patent Document 5). However, nothing has been known about the effect of promoting differentiation of sebaceous gland undifferentiated cells into sebaceous gland cells or the effect of promoting sebum synthesis by sebaceous gland cells.
本発明の目的は、皮脂腺細胞における皮脂合成を促進し、皮膚や頭皮における皮脂欠乏状態を根本的に改善し、持続性のある効果を有する皮脂合成促進剤を提供することにある。 An object of the present invention is to provide a sebum synthesis promoter that promotes sebum synthesis in sebaceous gland cells, radically improves the state of sebum deficiency in the skin and scalp, and has a durable effect.
本発明者らは、上記課題を解決すべく鋭意研究を重ねた結果、カガミグサの抽出物が、皮脂腺未分化細胞から皮脂腺細胞への分化を促進する作用とともに、皮脂腺細胞による皮脂合成を促進する作用を有することを見出し、本発明を完成するに至った。 As a result of intensive studies to solve the above-mentioned problems, the present inventors have found that the extract of crayfish promotes sebum synthesis by sebaceous gland cells as well as promotes differentiation from sebaceous gland undifferentiated cells to sebaceous gland cells. As a result, the present invention has been completed.
すなわち、本発明は以下の発明を包含する。
（１）カガミグサの抽出物を有効成分として含有する、皮脂合成促進剤。
（２）カガミグサの抽出物を有効成分として含有する、皮脂腺未分化細胞から皮脂腺細胞への分化促進剤。
（３）（１）または（２）に記載の剤を含む、皮膚外用組成物。
（４）皮膚外用組成物が医薬品または医薬部外品である、（３）に記載の皮膚外用組成物。
（５）皮膚外用組成物が化粧品である、（３）に記載の皮膚外用組成物。
（６）（１）または（２）に記載の剤を含む、飲食品。
（７）飲食品が、健康食品、機能性食品、特定保健用食品、または栄養補助食品である、（６）に記載の飲食品。
That is, the present invention includes the following inventions.
(1) A sebum synthesis promoter containing an extract of Rhizopus as an active ingredient.
(2) An agent for promoting differentiation from sebaceous gland undifferentiated cells to sebaceous gland cells, which contains an extract of crayfish as an active ingredient.
(3) A composition for external use on skin, comprising the agent according to (1) or (2).
(4) The external composition for skin according to (3), wherein the external composition for skin is a pharmaceutical product or a quasi-drug.
(5) The external composition for skin according to (3), wherein the external composition for skin is a cosmetic.
(6) Food / beverage products containing the agent as described in (1) or (2).
(7) The food or drink according to (6), wherein the food or drink is a health food, a functional food, a food for specified health use, or a dietary supplement.
本発明の皮脂合成促進剤は、皮脂腺細胞による皮脂の合成を促進することができるので、皮脂欠乏による皮膚や頭皮のかさつき、皮脂欠乏症（乾皮症）などの皮膚疾患を予防、改善または治療することができる。また、本発明の皮脂合成促進剤の有効成分であるカガミグサの抽出物は、皮脂腺未分化細胞から皮脂腺細胞への分化を促進する作用も有するため、皮脂合成および分泌器官である皮脂腺細胞が増加し、皮脂欠乏状態を根本的に改善することができ、持続性のある効果が得られる。また本発明の皮脂合成促進剤は、作用が緩和な植物の抽出物を有効成分とするから、副作用がなく安全性が高い。よって、化粧料、医薬品、医薬部外品、飲食品に安心して使用できる。 Since the sebum synthesis promoter of the present invention can promote the synthesis of sebum by sebaceous gland cells, it prevents, ameliorates or treats skin diseases such as skin and scalp bulk due to sebum deficiency and sebum deficiency (psoriasis). be able to. In addition, the extract of Kagamigusa, which is an active ingredient of the sebum synthesis promoter of the present invention, also has an action of promoting the differentiation from sebaceous gland undifferentiated cells to sebaceous gland cells. In addition, the sebum-deficient state can be fundamentally improved, and a durable effect can be obtained. Moreover, since the sebum synthesis promoter of the present invention uses a plant extract with a mild action as an active ingredient, it has no side effects and is highly safe. Therefore, it can be used with confidence in cosmetics, pharmaceuticals, quasi drugs, and food and drinks.
以下に、本発明について詳細に述べる。
本発明の皮脂合成促進剤は、カガミグサの抽出物を有効成分として含有する。本発明に用いるカガミグサ（学名：Ampelopsis japonica）はブドウ科ブドウ属に属する中国原産の蔓性多年草植物である。カガミグサの根茎は生薬で白斂（びゃくれん）と称し、腫れものや打撲傷、火傷の止痛などの民間療法に用いられている。
The present invention will be described in detail below.
The sebum synthesis promoter according to the present invention contains an extract of Rhizopus as an active ingredient. The crayfish (Ampelopsis japonica) used in the present invention is a vine perennial plant native to China belonging to the genus Grapeaceae. The rhizome of Kagamigusa is a herbal medicine called biakuren and is used for folk remedies such as swelling, bruises, and pain relief.
本発明において、カガミグサの抽出物は、植物体全体（全草）、あるいは、根、葉、茎、花、芽、実、種子等の植物体の一部またはそれらの混合物の抽出物をいうが、根の抽出物が好ましい。また、抽出には、これらの植物体をそのまま使用してもよく、乾燥、粉砕、細切等の処理を行ってもよい。 In the present invention, the extract of the chamomile is a whole plant (whole plant) or an extract of a part of a plant body such as root, leaf, stem, flower, bud, fruit, seed or a mixture thereof. Root extract is preferred. In addition, these plants may be used as they are for extraction, or may be subjected to treatments such as drying, pulverization and shredding.
抽出方法は、特に限定されないが、水もしくは熱水、または水と有機溶媒の混合溶媒を用い、攪拌またはカラム抽出する方法により行うことができる。有機溶媒としては、アルコール類、エーテル類、エステル類などを用いることができるが、エタノール、メタノール、アセトン等の水溶性有機溶媒が好ましく、これらの一種又は二種以上を用いてもよい。 The extraction method is not particularly limited, and can be performed by stirring or column extraction using water or hot water, or a mixed solvent of water and an organic solvent. As the organic solvent, alcohols, ethers, esters, and the like can be used, but water-soluble organic solvents such as ethanol, methanol, and acetone are preferable, and one or more of these may be used.
特に好ましい抽出溶媒としては、水、または水−エタノール系の混合極性溶媒が挙げられる。溶媒の使用量については、特に限定はなく、例えば上記カガミグサの根部（乾燥重量）に対し、１０倍以上、好ましくは２０倍以上であればよいが、抽出後に濃縮を行なったり、単離したりする場合の操作の便宜上１００倍以下であることが好ましい。また、抽出温度や時間は、用いる溶媒の種類によるが、例えば、１０〜１００℃、好ましくは３０〜９０℃で、３０分〜２４時間、好ましくは１〜１０時間を例示することができる。また、抽出物は、抽出した溶液のまま用いてもよいが、必要に応じて、その効果に影響のない範囲で、濃縮（有機溶媒、減圧濃縮、膜濃縮などによる濃縮）、希釈、濾過、活性炭等による脱色、脱臭、エタノール沈殿等の処理を行ってから用いてもよい。さらには、抽出した溶液を濃縮乾固、噴霧乾燥、凍結乾燥等の処理を行い、乾燥物として用いてもよい。 Particularly preferred extraction solvents include water or water-ethanol mixed polar solvents. The amount of the solvent used is not particularly limited, and for example, it may be 10 times or more, preferably 20 times or more, relative to the root part (dry weight) of the above-mentioned crayfish, but it is concentrated or isolated after extraction. For convenience of operation, it is preferably 100 times or less. Moreover, although extraction temperature and time depend on the kind of solvent to be used, for example, it is 10-100 degreeC, Preferably it is 30-90 degreeC, 30 minutes-24 hours, Preferably it can illustrate 1 to 10 hours. In addition, the extract may be used as it is in the extracted solution, but if necessary, in a range that does not affect the effect, concentration (concentration by organic solvent, vacuum concentration, membrane concentration, etc.), dilution, filtration, You may use, after performing processing, such as decoloring by activated carbon, deodorizing, ethanol precipitation. Further, the extracted solution may be subjected to a treatment such as concentration to dryness, spray drying, freeze drying, etc., and used as a dried product.
本発明において「皮脂合成促進」とは、皮脂腺細胞における脂肪酸グリセリンエステルを主成分とする脂質の合成促進をいうが、皮脂腺未分化細胞から皮脂腺細胞への分化誘導促進、および、皮脂腺細胞で合成された上記脂質の皮膚表面への分泌促進をも包含する。従って、本発明の皮脂合成促進剤は、皮脂腺未分化細胞から皮脂腺細胞への分化促進剤
としても用いることができる。
In the present invention, “stimulation of sebum synthesis” refers to the promotion of synthesis of lipids mainly composed of fatty acid glycerin ester in sebaceous gland cells, and promotes differentiation induction from sebaceous gland undifferentiated cells to sebaceous cells and is synthesized in sebaceous gland cells. Furthermore, it also includes the promotion of secretion of the lipids to the skin surface. Therefore, the sebum synthesis promoter of the present invention can also be used as a differentiation promoter from sebaceous gland undifferentiated cells to sebaceous cells.
また、本発明の皮脂合成促進剤は、皮脂腺未分化細胞から皮脂腺細胞へ効率的に分化誘導させるための細胞培養用添加剤、研究用試薬としても使用することができる。 The sebum synthesis promoter of the present invention can also be used as an additive for cell culture and a research reagent for efficiently inducing differentiation from sebaceous gland undifferentiated cells to sebaceous gland cells.
本発明の皮脂合成促進剤を生体内に投与する場合は、そのまま投与することも可能であるが、本発明の効果を損なわない範囲で適当な添加物とともに皮膚外用組成物に配合して提供することが好ましい。本発明の皮膚外用組成物には、医薬品、医薬部外品、化粧品などが含まれる。 When the sebum synthesis promoter of the present invention is administered in vivo, it can be administered as it is, but it is provided by blending it into a composition for external use with appropriate additives as long as the effects of the present invention are not impaired. It is preferable. The skin external composition of the present invention includes pharmaceuticals, quasi drugs, cosmetics and the like.
本発明の皮脂合成促進剤は、皮脂腺細胞による皮脂の合成を促進することができるので、当該剤を含む皮膚外用組成物は、皮脂分泌の低下が原因と考えられている種々の皮膚の障害や損傷を予防、改善、および治療するのに有効である。ここで、皮脂分泌の低下による皮膚の障害や損傷としては、限定はされないが、皮脂欠乏症（乾皮症）、皮脂欠乏性湿疹、皮膚掻痒症、手湿疹、アトピー性皮膚炎、乾燥肌、ひび、あかぎれなどが挙げられ、乾性フケ、髪のぱさつきやツヤ不足、抜け毛や薄毛などの頭皮や毛髪の障害や損傷も含まれる。 Since the sebum synthesis promoting agent of the present invention can promote the synthesis of sebum by sebaceous gland cells, the composition for external use of the skin containing the agent has various skin disorders and Effective in preventing, ameliorating, and treating damage. Here, the skin damage or damage caused by the decrease in sebum secretion is not limited, but is sebum deficiency (xeroderma), sebum-deficient eczema, skin pruritus, hand eczema, atopic dermatitis, dry skin, cracks , Redhead dandruff, hairiness and lack of luster, scalp and hair damage and damage such as hair loss and thinning hair are also included.
本発明の皮脂合成促進剤を医薬品に配合する場合は、薬理学的及び製剤学的に許容しうる添加物と混合し、患部に適用するのに適した製剤形態の各種製剤に製剤化することができる。薬理学的及び製剤学的に許容しうる添加物としては、その剤形、用途に応じて賦形剤、増粘剤、等張化剤、ｐＨ調節剤、安定化剤、防腐剤、保存剤、分散剤、乳化剤、ゲル化剤、色素、香料等を用いることができる。本発明の医薬品に適した形態は外用製剤であり、例えば、軟膏剤、クリーム剤、ゲル剤、液剤、貼付剤などが挙げられる。軟膏剤は、均質な半固形状の外用製剤をいい、油脂性軟膏、乳剤性軟膏、水溶性軟膏を含む。ゲル剤は、水不溶性成分の抱水化合物を水性液に懸濁した外用製剤をいう。液剤は、液状の外用製剤をいい、ローション剤、懸濁剤、乳剤、リニメント剤等を含む。 When the sebum synthesis promoter of the present invention is added to a pharmaceutical product, it should be mixed with pharmacologically and pharmaceutically acceptable additives and formulated into various preparations suitable for application to the affected area. Can do. Pharmacologically and pharmaceutically acceptable additives include excipients, thickeners, tonicity agents, pH regulators, stabilizers, preservatives, preservatives depending on the dosage form and application. , Dispersants, emulsifiers, gelling agents, pigments, fragrances and the like can be used. A form suitable for the pharmaceutical product of the present invention is an external preparation, and examples thereof include an ointment, a cream, a gel, a liquid, and a patch. The ointment refers to a homogeneous semi-solid external preparation, and includes an oily ointment, an emulsion ointment, and a water-soluble ointment. The gel is an external preparation in which a water-insoluble component hydrate compound is suspended in an aqueous liquid. The liquid preparation refers to a liquid external preparation and includes lotions, suspensions, emulsions, liniments and the like.
本発明の皮脂合成促進剤を医薬部外品や化粧品に配合する場合は、その剤形は、水溶液系、可溶化系、乳化系、粉末系、粉末分散系、油液系、ゲル系、軟膏系、エアゾール系、水−油二層系、または水−油−粉末三層系等のいずれでもよい。また、当該医薬部外品や化粧品は、皮脂合成促進剤とともに、皮膚外用組成物において通常使用されている各種成分、添加剤、基剤等をその種類に応じて選択し、適宜配合し、当分野で公知の手法に従って製造することができる。その形態は、液状、乳液状、クリーム状、ゲル状、ペースト状、スプレー状等のいずれであってもよい。配合成分としては、例えば、油脂類（オリーブ油、ヤシ油、月見草油、ホホバ油、ヒマシ油、硬化ヒマシ油等）、ロウ類（ラノリン、ミツロウ、カルナウバロウ等）、炭化水素類（流動パラフィン、スクワレン、スクワラン、ワセリン等）、脂肪酸類（ラウリン酸、ミリスチン酸、パルミチン酸、ステアリン酸、ベヘニン酸等）、高級アルコール類（ミリスチルアルコール、セタノール、セトステアリルアルコール、ステアリルアルコール、ベヘニルアルコール等）、エステル類（ミリスチン酸イソプロピル、パルミチン酸イソプロピル、オクタン酸セチル、トリオクタン酸グリセリン、ミリスチン酸オクチルドデシル、ステアリン酸オクチル、ステアリン酸ステアリル等）、有機酸類（クエン酸、乳酸、α-ヒドロキシ酢酸、ピロリドンカルボン酸等）、糖類（マルチトール、ソルビトール、キシロビオース、N-アセチル-D-グルコサミン等）、蛋白質及び蛋白質の加水分解物、アミノ酸類及びその塩、ビタミン類、植物・動物抽出成分、種々の界面活性剤、保湿剤、紫外線吸収剤、抗酸化剤、安定化剤、防腐剤、殺菌剤、香料等が挙げられる。 When the sebum synthesis accelerator of the present invention is blended into a quasi-drug or cosmetic, the dosage form is an aqueous system, a solubilizing system, an emulsifying system, a powder system, a powder dispersion system, an oil liquid system, a gel system, or an ointment. Any of a system, an aerosol system, a water-oil two-layer system, or a water-oil-powder three-layer system may be used. In addition to the sebum synthesis accelerator, the quasi-drug and cosmetics are selected from various ingredients, additives, bases, and the like that are usually used in compositions for external use according to the type, and appropriately blended. It can be produced according to techniques known in the art. The form may be liquid, emulsion, cream, gel, paste, spray or the like. Examples of the ingredients include oils and fats (olive oil, coconut oil, evening primrose oil, jojoba oil, castor oil, hydrogenated castor oil, etc.), waxes (lanolin, beeswax, carnauba wax, etc.), hydrocarbons (liquid paraffin, squalene, Squalane, petrolatum, etc.), fatty acids (lauric acid, myristic acid, palmitic acid, stearic acid, behenic acid etc.), higher alcohols (myristyl alcohol, cetanol, cetostearyl alcohol, stearyl alcohol, behenyl alcohol etc.), esters (myristin) Isopropyl acid, isopropyl palmitate, cetyl octanoate, glyceryl trioctanoate, octyldodecyl myristate, octyl stearate, stearyl stearate, etc., organic acids (citric acid, lactic acid, α-hydroxyacetic acid, pyrrolidone cal Acid, etc.), sugars (maltitol, sorbitol, xylobiose, N-acetyl-D-glucosamine, etc.), proteins and protein hydrolysates, amino acids and salts thereof, vitamins, plant / animal extracts, various interfaces Examples include activators, humectants, ultraviolet absorbers, antioxidants, stabilizers, preservatives, bactericides, and fragrances.
医薬部外品や化粧品の種類としては、例えば、化粧水、乳液、ジェル、美容液、一般クリーム、日焼け止めクリーム、パック、マスク、洗顔料、化粧石鹸、ファンデーション、おしろい、浴用剤、ボディローション、ボディシャンプー、ヘアシャンプー、ヘアコンディショナー、頭皮用ローション、頭皮用クリーム、ヘアトニック、育毛剤等が挙げられる。 The types of quasi-drugs and cosmetics include, for example, lotions, emulsions, gels, cosmetics, general creams, sun creams, packs, masks, facial cleansers, cosmetic soaps, foundations, funniers, bath preparations, body lotions, Examples include body shampoos, hair shampoos, hair conditioners, scalp lotions, scalp creams, hair tonics, and hair restorers.
本発明の皮膚外用組成物における皮脂合成促進剤の含有量は、皮脂腺未分化細胞から皮脂腺細胞への分化促進作用とともに、皮脂腺細胞における皮脂合成促進作用を発揮できる量である限り特に限定はされないが、例えばカガミグサの抽出物の乾燥固形物重量として０．００００１〜１０重量％が好ましく、０．０００１〜１重量％がより好ましい。上記の量はあくまで例示であって、組成物の種類や形態、一般的な使用量、効能・効果、及びコストなどを考慮して適宜設定・調整すればよい。 The content of the sebum synthesis promoter in the composition for external use of the present invention is not particularly limited as long as it is an amount capable of exerting a sebum synthesis promoting action in sebaceous gland cells as well as a differentiation promoting action from sebaceous gland undifferentiated cells to sebaceous gland cells. For example, 0.00001 to 10% by weight is preferable as the dry solid weight of the extract of the crayfish, and 0.0001 to 1% by weight is more preferable. The above amounts are merely examples, and may be appropriately set and adjusted in consideration of the type and form of the composition, the general usage amount, efficacy / effect, cost, and the like.
また、本発明の皮脂合成促進剤は、飲食品にも配合できる。本発明において、飲食品とは、健康食品、機能性食品、栄養補助食品、または特定保健用食品を含む意味で用いられる。飲食品の形態は、食用に適した形態、例えば、固形状、液状、顆粒状、粒状、粉末状、カプセル状、クリーム状、ペースト状のいずれであってもよい。 Moreover, the sebum synthesis promoter of this invention can be mix | blended with food-drinks. In the present invention, the food / beverage product is used to mean including a health food, a functional food, a dietary supplement, or a food for specified health use. The form of the food or drink may be any form suitable for edible use, for example, solid, liquid, granular, granular, powder, capsule, cream, or paste.
飲食品の種類としては、パン類、麺類、菓子類、乳製品、水産・畜産加工食品、油脂及び油脂加工食品、調味料、各種飲料（清涼飲料、炭酸飲料、美容ドリンク、栄養飲料、果実飲料、乳飲料など）および該飲料の濃縮原液及び調整用粉末等が挙げられるが、これらに限定はされない。 The types of food and drink include bread, noodles, confectionery, dairy products, processed fishery and livestock products, processed oils and fats, processed foods, seasonings, various beverages (soft drinks, carbonated drinks, beauty drinks, nutritional drinks, fruit drinks) , Milk beverages, etc.) and concentrated beverages and powders for adjustment of the beverages, but are not limited thereto.
本発明の飲食品は、その種類に応じて通常使用される添加物を適宜配合してもよい。添加物としては、食品衛生上許容されうる添加物であればいずれも使用できるが、例えば、ブドウ糖、ショ糖、果糖、異性化液糖、アスパルテーム、ステビア等の甘味料；クエン酸、リンゴ酸、酒石酸等の酸味料；デキストリン、澱粉等の賦形剤；結合剤、希釈剤、香料、着色料、緩衝剤、増粘剤、ゲル化剤、安定剤、保存剤、乳化剤、分散剤、懸濁化剤、防腐剤などが挙げられる。 The food / beverage products of the present invention may be appropriately blended with additives usually used depending on the type. As the additive, any food hygiene-acceptable additive can be used. For example, sweeteners such as glucose, sucrose, fructose, isomerized liquid sugar, aspartame, stevia; citric acid, malic acid, Acidic agents such as tartaric acid; excipients such as dextrin and starch; binders, diluents, fragrances, colorants, buffers, thickeners, gelling agents, stabilizers, preservatives, emulsifiers, dispersants, suspensions Agents, preservatives and the like.
本発明の飲食品におけるカガミグサの抽出物の配合量は、皮脂腺未分化細胞から皮脂腺細胞への分化促進作用と皮脂腺細胞における皮脂合成促進作用を発揮できる量であればよいが、対象飲食品の一般的な摂取量、飲食品の形態、効能・効果、呈味性、嗜好性及びコストなどを考慮して適宜設定すればよい。 The compounding amount of the extract of chamomilesa in the food or drink of the present invention may be any amount that can exhibit differentiation promoting action from sebaceous gland undifferentiated cells to sebaceous gland cells and sebum synthesis promoting action in sebaceous gland cells. May be set as appropriate in consideration of typical intake, form of food and drink, efficacy / effect, taste, palatability and cost.
以下、実施例により本発明をさらに具体的に説明する。但し、本発明はこれらに限定されるものではない。 Hereinafter, the present invention will be described more specifically with reference to examples. However, the present invention is not limited to these.
［実施例１］
カガミグサの抽出物を以下のとおり製造した。
（製造例１）カガミグサ根の熱水抽出物の調製
カガミグサ（根の乾燥品）1００ｇに精製水を１Ｌ加え、９０〜１００℃で２時間抽出した後、濾過し、その濾液を濃縮し、凍結乾燥してカガミグサ根の熱水抽出物３０ｇを得た。
[Example 1]
An extract of the crayfish was produced as follows.
(Production Example 1) Preparation of hot water extract of Kagamusa root 1 L of purified water was added to 100 g of Kagamusa (dried root product), extracted at 90-100 ° C for 2 hours, filtered, and the filtrate was concentrated and frozen. Drying was performed to obtain 30 g of a hot water extract of crayfish root.
（製造例２）カガミグサ根の５０％エタノール抽出物の調製
カガミグサ（根の乾燥品）1００gに５０％エタノール水溶液を１Ｌ加え、室温で1週間抽出した後、濾過し、その濾液を減圧濃縮し、凍結乾燥してカガミグサ根の５０％エタノール抽出物２７ｇを得た。
(Production Example 2) Preparation of 50% ethanol extract of scallop roots 1L of 50% ethanol aqueous solution was added to 100 g of scallops (dried root product), extracted for 1 week at room temperature, filtered, and the filtrate was concentrated under reduced pressure. It was freeze-dried to obtain 27 g of a 50% ethanol extract of cyprus root.
（製造例３）カガミグサ根のエタノール抽出物の調製
カガミグサ（根の乾燥品）1００gにエタノールを１Ｌ加え、室温で1週間抽出した後、濾過し、その濾液を減圧濃縮し、凍結乾燥してカガミグサ根のエタノール抽出物２５ｇを得た。
(Manufacturing Example 3) Preparation of ethanol extract of Kagamigusa Root Add 1 L of ethanol to 100 g of Kagamigusa (dried root product), extract at room temperature for 1 week, filter, concentrate the filtrate under reduced pressure, freeze-dry and freeze it. 25 g of ethanol extract of roots was obtained.
（製造例４）カガミグサ全草の熱水抽出物の調製
カガミグサ（全草の乾燥品）1００gに精製水を１Ｌ加え、９０〜１００℃で２時間抽出した後、濾過し、その濾液を濃縮し、凍結乾燥してカガミグサ全草の熱水抽出物３１ｇを得た。
(Manufacture example 4) Preparation of hot water extract of the crayfish whole plant 1L of purified water is added to 100 g of the cyprus grass (dry product of whole plant), extracted at 90-100 ° C for 2 hours, filtered, and the filtrate is concentrated. Then, freeze-dried to obtain 31 g of a hot water extract of the whole plant.
（製造例５）カガミグサ全草５０％エタノール抽出物の調製
カガミグサ（全草の乾燥品）1００gに５０％エタノール水溶液を１Ｌ加え、室温で1週間抽出した後、濾過し、その濾液を減圧濃縮し、凍結乾燥することによりカガミグサ全草の５０％エタノール抽出物２７ｇを得た。
(Manufacture example 5) Preparation of 50% ethanol extract of Kagamigusa whole plant Add 1 L of 50% ethanol aqueous solution to 100 g of Kagamigusa (dry product of whole plant), extract for 1 week at room temperature, filter, and concentrate the filtrate under reduced pressure. By freeze-drying, 27 g of a 50% ethanol extract of the cloverfish whole plant was obtained.
（製造例６）カガミグサ全草のエタノール抽出物の調製
カガミグサ（全草の乾燥品）1００gにエタノールを１Ｌ加え、室温で1週間抽出した後、濾過し、その濾液を減圧濃縮し、凍結乾燥することによりカガミグサ全草のエタノール抽出物２４ｇを得た。
(Production Example 6) Preparation of Ethanol Extract of Whole Crabgrass 1L of ethanol was added to 100g of Crabgrass (whole plant dried product), extracted for 1 week at room temperature, filtered, and the filtrate was concentrated under reduced pressure and lyophilized. As a result, 24 g of an ethanol extract of the cyprus grass was obtained.
[実施例２]
カガミグサの抽出物の効果の評価実験を次のとおり行った。
（試験例１）皮脂腺未分化細胞から皮脂腺細胞への分化促進効果の評価
実施例１で製造したカガミグサの抽出物（製造例１〜６）の皮脂腺未分化細胞から皮脂腺細胞への分化効率に及ぼす影響を、皮脂腺細胞の特異的マーカーであるPparg（Peroxisome Proliferator-Activated Receptor γ）、Plin1（Perilipin1）、Fabp4（Fatty Acid Binding Protein 4）の発現を指標に評価した。具体的方法について以下に記載する。
[Example 2]
An experiment for evaluating the effect of the extract of Crayfish was performed as follows.
(Test Example 1) Evaluation of differentiation promoting effect from sebaceous gland undifferentiated cells to sebaceous gland cells The effect of the extract of Kagamigusa manufactured in Example 1 (Production Examples 1 to 6) on the differentiation efficiency from sebaceous gland undifferentiated cells to sebaceous gland cells The effect was evaluated using the expression of Pparg (Peroxisome Proliferator-Activated Receptor γ), Plin1 (Perilipin1), and Fabp4 (Fatty Acid Binding Protein 4) as specific markers of sebaceous gland cells. The specific method is described below.
ハムスター皮脂腺細胞増殖培地(KURABO社製)を用いて培養したハムスター皮脂腺未分化細胞(KURABO社製)を24ウェルディッシュに5x104個ずつ播種し、その後、培地を皮脂腺細胞分化誘導培地（KURABO社製）に置換することにより、分化誘導を行った。その際、実施例１で製造したカガミグサの抽出物(製造例１〜６)を最終濃度が0.001%になるように添加し、６日間培養を続けた。 5 x 10 4 hamster sebaceous gland undifferentiated cells (manufactured by KURABO) cultured in hamster sebaceous gland cell growth medium (manufactured by KURABO) are seeded in 24 well dishes at a time, and then the medium is sebaceous gland cell differentiation inducing medium (manufactured by KURABO). ) To induce differentiation. At that time, the extract of Kagamigusa (Production Examples 1 to 6) produced in Example 1 was added to a final concentration of 0.001%, and the culture was continued for 6 days.
分化誘導後６日目の細胞を、PBS(-)にて2回洗浄し、RNA iso Plus （Takara社製）によって細胞からRNAを抽出した。2-STEPリアルタイムPCRキット（Applied Biosystems社製）を用いて、RNAをcDNAに逆転写後、ABI7300（Applied Biosystems）により、上記マーカー遺伝子(Pparg、Plin1、Fabp4)増幅用プライマーセットを用いてリアルタイムPCR(95℃:15秒間、60℃:30秒間、40サイクル)を実施し、各遺伝子の遺伝子発現を確認した。その他の操作は定められた方法に従って実施した。 Cells on the 6th day after differentiation induction were washed twice with PBS (−), and RNA was extracted from the cells with RNA iso Plus (manufactured by Takara). Using 2-STEP real-time PCR kit (Applied Biosystems), RNA is reverse transcribed to cDNA, then ABI7300 (Applied Biosystems) is used for real-time PCR using the above marker gene (Pparg, Plin1, Fabp4) amplification primer set (95 ° C .: 15 seconds, 60 ° C .: 30 seconds, 40 cycles) was carried out to confirm gene expression of each gene. Other operations were carried out in accordance with established methods.
（Pparg遺伝子用プライマーセット）
フォワードプライマー：5'-ATGTCTCACAATGCCATCAGGTT-3'（配列番号１）
リバースプライマー：5'-CCGCCAACAGCTTCTCCTT-3'（配列番号２）
（Plin1遺伝子用プライマーセット）
フォワードプライマー：5'-TCTGAGCTGAAAGGCACCATCT-3'（配列番号３）
リバースプライマー：5'-GATGGGCACACTGATGCTGTT-3'（配列番号４）
（Fabp4遺伝子用プライマーセット）
フォワードプライマー：5'-TGGCCAAACCCATCATGAT-3'（配列番号５）
リバースプライマー：5'-TGTGCTCTCTGTTCGGATGGT-3'（配列番号６）
（内部標準グリセルアルデヒド３リン酸デヒドロゲナーゼ（Gapdh）遺伝子用プライマーセット）
フォワードプライマー：5'-TCACATGTCGCCTGGAGAAAG-3'（配列番号７）
リバースプライマー：5'-GCCTTCGGATGCCTGCTT-3'（配列番号８）
(Primer set for Pparg gene)
Forward primer: 5'-ATGTCTCACAATGCCATCAGGTT-3 '(SEQ ID NO: 1)
Reverse primer: 5'-CCGCCAACAGCTTCTCCTT-3 '(SEQ ID NO: 2)
(Primer set for Plin1 gene)
Forward primer: 5'-TCTGAGCTGAAAGGCACCATCT-3 '(SEQ ID NO: 3)
Reverse primer: 5'-GATGGGCACACTGATGCTGTT-3 '(SEQ ID NO: 4)
(Fabp4 gene primer set)
Forward primer: 5'-TGGCCAAACCCATCATGAT-3 '(SEQ ID NO: 5)
Reverse primer: 5'-TGTGCTCTCTGTTCGGATGGT-3 '(SEQ ID NO: 6)
(Internal standard glyceraldehyde 3-phosphate dehydrogenase (Gapdh) gene primer set)
Forward primer: 5'-TCACATGTCGCCTGGAGAAAG-3 '(SEQ ID NO: 7)
Reverse primer: 5'-GCCTTCGGATGCCTGCTT-3 '(SEQ ID NO: 8)
各細胞の皮脂腺細胞への分化誘導効率については、カガミグサの抽出物を添加せずに分化誘導した細胞における各遺伝子mRNAの発現量を内部標準であるGapdh mRNAの発現量に対する割合として算出した各遺伝子の相対発現量（各遺伝子発現量/ Gapdh遺伝子の発現量）の値を1.0とし、これに対し、カガミグサの抽出物を添加して培養した細胞における各遺伝子の相対発現量の値を算出し、評価した。結果を表１に示す。 As for the differentiation induction efficiency of each cell into sebaceous gland cells, the expression level of each gene mRNA in the cells induced to differentiate without the addition of the extract of crayfish was calculated as a ratio to the expression level of Gapdh mRNA as an internal standard. The relative expression level of each gene (the expression level of each gene / the expression level of the Gapdh gene) was set to 1.0. On the other hand, the value of the relative expression level of each gene in the cells cultured with the addition of the extract of Kagamigusa was calculated. evaluated. The results are shown in Table 1.
表１に示すとおり、カガミグサの抽出物（製造例１〜６）の全てに、顕著な皮脂腺未分化細胞から皮脂腺細胞への分化誘導促進効果が認められた。 As shown in Table 1, all of the extracts of Kagamusa (Production Examples 1 to 6) showed a remarkable effect of promoting differentiation induction from sebaceous gland undifferentiated cells to sebaceous gland cells.
（試験例２）皮脂合成促進効果の評価
ハムスター皮脂腺細胞増殖培地を用いて培養したハムスター皮脂腺未分化細胞を24ウェルディッシュに5x104個ずつ播種し、その後、培地を皮脂腺細胞分化誘導培地に置換することにより、分化誘導を行った。その際、実施例１で製造したカガミグサの抽出物(製造例１〜６)を最終濃度が0.001%になるように添加し、12日間培養を続けた。培養12日後に細胞を回収し、PBS(-)にて2回洗浄し、脂質合成測定キット(KURABO社製)を用いて皮脂腺細胞で合成された脂質の測定を定められた方法に従って実施した。
(Test Example 2) Evaluation of the effect of promoting sebum synthesis Inoculate 5x10 4 hamster sebaceous gland undifferentiated cells cultured in hamster sebaceous gland cell growth medium in a 24-well dish, and then replace the medium with a sebaceous cell differentiation-inducing medium. Thus, differentiation induction was performed. At that time, the extract of Kagamigusa manufactured in Example 1 (Production Examples 1 to 6) was added so that the final concentration was 0.001%, and the culture was continued for 12 days. After 12 days of culture, the cells were collected, washed twice with PBS (−), and the lipid synthesized in the sebaceous gland cells was measured according to a predetermined method using a lipid synthesis measurement kit (manufactured by KURABO).
皮脂合成促進効果は、試料を添加せずに培養した細胞における脂質の合成量をコントロール（1.0)とし、試料を添加して培養した細胞における脂質の合成量のコントロールの脂質の合成量に対する割合（コントロール比）を算出した。結果を表２に示す。 The effect of promoting sebum synthesis is the ratio of the amount of lipid synthesis in cells cultured without adding the sample to the control (1.0), and the ratio of the amount of lipid synthesis in the cells cultured with the sample added to the amount of synthesized lipid ( Control ratio) was calculated. The results are shown in Table 2.
表２に示すとおり、カガミグサの抽出物（製造例１〜６）の全てに、顕著な皮脂腺細胞における皮脂合成促進効果が認められた。 As shown in Table 2, all of the extracts of Kagamusa (Production Examples 1 to 6) showed a remarkable effect of promoting sebum synthesis in sebaceous gland cells.
[実施例３]製品の処方例
製造例１〜６で製造したカガミグサの抽出物を配合した製品の処方例を以下に示す。
（処方例１）ローション
処方 配合量(重量％）
１．カガミグサの抽出物 ０．１
２．１，３−ブチレングリコール ８．０
３．グリセリン ２．０
４．キサンタンガム ０．０２
５．クエン酸 ０．０１
６．クエン酸ナトリウム ０．１
７．エタノール ５．０
８．パラオキシ安息香酸メチル ０．１
９．ポリオキシエチレン硬化ヒマシ油（４０Ｅ．Ｏ．） ０．１
１０．香料 ０．１
１１．精製水 残量
[Example 3] Formulation example of product The formulation example of the product which mix | blended the extract of Kagamigusa manufactured in manufacture examples 1-6 is shown below.
(Formulation Example 1) Lotion Formulation Blending amount (% by weight)
1. Oyster extract 0.1
2. 1,3-butylene glycol 8.0
3. Glycerin 2.0
4). Xanthan gum 0.02
5. Citric acid 0.01
6). Sodium citrate 0.1
7). Ethanol 5.0
8). Methyl paraoxybenzoate 0.1
9. Polyoxyethylene hydrogenated castor oil (40E.O.) 0.1
10. Fragrance 0.1
11. Purified water remaining
成分１〜６及び１１と、成分７〜１０をそれぞれ均一に溶解した後、両者を混合し濾過しローションを調製する。 Components 1 to 6 and 11 and components 7 to 10 are uniformly dissolved, then both are mixed and filtered to prepare a lotion.
（処方例２） クリーム
処方 配合量(重量％）
１．カガミグサの抽出物 ０．１
２．スクワラン ５．５
３．オリーブ油 ３．０
４．ステアリン酸 ２．０
５．ミツロウ ２．０
６．ミリスチン酸オクチルドデシル ３．５
７．ポリオキシエチレンセチルエーテル（２０Ｅ．Ｏ．） ３．０
８．ベヘニルアルコール １．５
９．モノステアリン酸グリセリン ２．５
１０．香料 ０．１
１１．パラオキシ安息香酸メチル ０．２
１２．パラオキシ安息香酸エチル ０．０５
１３．１，３−ブチレングリコール ８．５
１４．精製水 残量
(Formulation example 2) Cream Formulation Blending amount (% by weight)
1. Oyster extract 0.1
2. Squalane 5.5
3. Olive oil 3.0
4). Stearic acid 2.0
5. Beeswax 2.0
6). Octyldodecyl myristate 3.5
7). Polyoxyethylene cetyl ether (20E.O.) 3.0
8). Behenyl alcohol 1.5
9. Glycerol monostearate2.5
10. Fragrance 0.1
11. Methyl paraoxybenzoate 0.2
12 Ethyl paraoxybenzoate 0.05
13.1,3-Butylene glycol 8.5
14 Purified water remaining
成分２〜９を加熱溶解して混合し、７０℃に保ち油相とする。成分１及び１１〜１４を加熱溶解して混合し、７５℃に保ち水相とする。次いで、油相に水相を加えて乳化して、かき混ぜながら冷却し、４５℃で成分１０を加え、さらに３０℃まで冷却して製品とする。 Ingredients 2-9 are dissolved by heating and mixed, and kept at 70 ° C. to obtain an oil phase. Ingredients 1 and 11 to 14 are dissolved by heating and mixed, and kept at 75 ° C. to form an aqueous phase. Next, the aqueous phase is added to the oil phase to emulsify, and the mixture is cooled while stirring. The component 10 is added at 45 ° C., and further cooled to 30 ° C. to obtain a product.
（処方例３）乳液
処方 配合量(重量％）
１．カガミグサの抽出物 ０．１
２．スクワラン ５．０
３．オリーブ油 ５．０
４．ホホバ油 ５．０
５．セタノール １．５
６．モノステアリン酸グリセリン ２．０
７．ポリオキシエチレンセチルエーテル（２０Ｅ．Ｏ．） ３．０
８．ポリオキシエチレンソルビタン
モノオレエート（２０Ｅ．Ｏ．） ２．０
９．香料 ０．１
１０．プロピレングリコール １．０
１１．グリセリン ２．０
１２．パラオキシ安息香酸メチル ０．２
１３．精製水 残量
(Prescription Example 3) Emulsion
Formulation amount (% by weight)
1. Oyster extract 0.1
2. Squalane 5.0
3. Olive oil 5.0
4). Jojoba oil 5.0
5. Cetanol 1.5
6). Glycerol monostearate 2.0
7). Polyoxyethylene cetyl ether (20E.O.) 3.0
8). Polyoxyethylene sorbitan monooleate (20E.O.) 2.0
9. Fragrance 0.1
10. Propylene glycol 1.0
11. Glycerin 2.0
12 Methyl paraoxybenzoate 0.2
13. Purified water remaining
成分２〜８を加熱溶解して混合し、７０℃に保ち油相とする。成分１及び１０〜１３を加熱溶解して混合し、７５℃に保ち水相とする。油相に水相を加えて乳化して、かき混ぜながら冷却し、４５℃で成分９を加え、さらに３０℃まで冷却して製品とする。 Ingredients 2 to 8 are dissolved by heating and mixed, and kept at 70 ° C. to obtain an oil phase. Ingredients 1 and 10-13 are dissolved by heating and mixed, and kept at 75 ° C. to form an aqueous phase. The aqueous phase is added to the oil phase to emulsify, and the mixture is cooled while stirring.
（処方例４）ゲル剤
処方 配合量(重量％）
１．カガミグサの抽出物 ０．１
２．エタノール ５．０
３．パラオキシ安息香酸メチル ０．１
４．ポリオキシエチレン硬化ヒマシ油 ０．１
５．香料 適量
６．１，３−ブチレングリコール ５．０
７．グリセリン ５．０
８．キサンタンガム ０．１
９．カルボキシビニルポリマー ０．２
１０．水酸化カリウム ０．２
１１．精製水 残量
(Formulation Example 4) Gel formulation Formulation amount (% by weight)
1. Oyster extract 0.1
2. Ethanol 5.0
3. Methyl paraoxybenzoate 0.1
4). Polyoxyethylene hydrogenated castor oil 0.1
5. Perfume proper amount 6.1,3-butylene glycol 5.0
7). Glycerin 5.0
8). Xanthan gum 0.1
9. Carboxyvinyl polymer 0.2
10. Potassium hydroxide 0.2
11. Purified water remaining
成分２〜５と、成分１及び６〜１１をそれぞれ均一に溶解し、両者を混合して製品とする。 Ingredients 2 to 5 and ingredients 1 and 6 to 11 are uniformly dissolved, and both are mixed to obtain a product.
（処方例５）軟膏
処方 配合量(重量％）
１．カガミグサの抽出物 ２．０
２．ポリオキシエチレンセチルエーテル（３０Ｅ．Ｏ．） ２．０
３．モノステアリン酸グリセリン １０．０
４．流動パラフィン ５．０
５．セタノール ６．０
６．パラオキシ安息香酸メチル ０．１
７．プロピレングリコール １０．０
８．精製水 残量
(Formulation Example 5) Ointment Formulation Formulation amount (% by weight)
1. Oyster extract 2.0
2. Polyoxyethylene cetyl ether (30E.O.) 2.0
3. Glycerol monostearate 10.0
4). Liquid paraffin 5.0
5. Cetanol 6.0
6). Methyl paraoxybenzoate 0.1
7). Propylene glycol 10.0
8). Purified water remaining
成分２〜５を加熱溶解して混合し、７０℃に保ち油相とする。成分１及び６〜８を加熱溶解して混合し、７５℃に保ち水相とする。油相に水相を加えて乳化し、かき混ぜながら３０℃まで冷却して製品とする。 Ingredients 2 to 5 are dissolved by heating and mixed, and kept at 70 ° C. to obtain an oil phase. Ingredients 1 and 6 to 8 are dissolved by heating and mixed, and kept at 75 ° C. to obtain an aqueous phase. The aqueous phase is added to the oil phase to emulsify, and the product is cooled to 30 ° C. with stirring to obtain a product.
（処方例６）パック
処方 配合量(重量％）
１．カガミグサの抽出物 ０．１
２．ポリビニルアルコール １２．０
３．エタノール ５．０
４．１，３−ブチレングリコール ８．０
５．パラオキシ安息香酸メチル ０．２
６．パラオキシエチレン硬化ヒマシ油（２０Ｅ．Ｏ．） ０．５
７．クエン酸 ０．１
８．クエン酸ナトリウム ０．３
９．香料 適量
１０．精製水 残量
成分１〜１０を均一に溶解し製品とする。
(Formulation example 6) Pack
Formulation amount (% by weight)
1. Oyster extract 0.1
2. Polyvinyl alcohol 12.0
3. Ethanol 5.0
4.1,3-Butylene glycol 8.0
5. Methyl paraoxybenzoate 0.2
6). Paraoxyethylene hydrogenated castor oil (20 EO) 0.5
7). Citric acid 0.1
8). Sodium citrate 0.3
9. Perfume appropriate amount10. Purified water remaining amount Ingredients 1 to 10 are uniformly dissolved to obtain a product.
（処方例７）ファンデーション
処方 配合量(重量％）
１．カガミグサの抽出物 １．０
２．ステアリン酸 ２．４
３．ポリオキシエチレンソルビタンモノステアレート（２０Ｅ．Ｏ．） １．０
４．ポリオキシエチレンセチルエーテル（２０Ｅ．Ｏ．） ２．０
５．セタノール １．０
６．液状ラノリン ２．０
７．流動パラフィン ３．０
８．ミリスチン酸イソプロピル ６．５
９．パラオキシ安息香酸ブチル ０．１
１０．カルボキシメチルセルロースナトリウム ０．１
１１．ベントナイト ０．５
１２．プロピレングリコール ４．０
１３．トリエタノールアミン １．１
１４．パラオキシ安息香酸メチル ０．２
１５．二酸化チタン ８．０
１６．タルク ４．０
１７．ベンガラ １．０
１８．黄酸化鉄 ２．０
１９．香料 適量
２０．精製水 残量
(Formulation example 7) Foundation Formulation Formulation amount (% by weight)
1. Oyster extract 1.0
2. Stearic acid 2.4
3. Polyoxyethylene sorbitan monostearate (20E.O.) 1.0
4). Polyoxyethylene cetyl ether (20E.O.) 2.0
5. Cetanol 1.0
6). Liquid lanolin 2.0
7). Liquid paraffin 3.0
8). Isopropyl myristate 6.5
9. Butyl paraoxybenzoate 0.1
10. Sodium carboxymethylcellulose 0.1
11. Bentonite 0.5
12 Propylene glycol 4.0
13. Triethanolamine 1.1
14 Methyl paraoxybenzoate 0.2
15. Titanium dioxide 8.0
16. Talc 4.0
17. Bengala 1.0
18. Yellow iron oxide 2.0
19. Perfume proper amount20. Purified water remaining
成分２〜９を加熱溶解し、８０℃に保ち油相とする。成分２０に成分１０をよく膨潤させ、続いて、成分１及び１１〜１４を加えて均一に混合する。これに粉砕機で粉砕混合した成分１５〜１８を加え、水相とする。水相を８０℃に昇温し、油相に水相を徐々に加え乳化する。その後、撹拌しながら冷却し、４５℃で成分１９を加え、３０℃まで冷却して製品とする。 Ingredients 2 to 9 are dissolved by heating and kept at 80 ° C. to form an oil phase. Swell component 10 well with component 20, then add components 1 and 11-14 and mix uniformly. To this, ingredients 15 to 18 pulverized and mixed with a pulverizer are added to obtain an aqueous phase. The aqueous phase is heated to 80 ° C., and the aqueous phase is gradually added to the oil phase to emulsify. Then, it cools with stirring, and the component 19 is added at 45 degreeC, and it cools to 30 degreeC to make a product.
（処方例８）ハンドクリーム
処方 配合量(重量％）
１．カガミグサの抽出物 ０．５
２．セタノール ４．０
３．ワセリン ２．０
４．流動パラフィン １０．０
５．酢酸トコフェロール ０．１
６．ビタミンＤ ０．１
７．尿素 ２．０
８．グリセリン ２０．０
９．ポリオキシエチレン（６０）イソステアリン酸グリセリン ２．５
１０．モノステアリン酸グリセリン １．５
１１．防腐剤 ０．１
１２．香料 適量
１３．精製水 残量
(Formulation example 8) Hand cream Formulation Formulation amount (% by weight)
1. Oyster extract 0.5
2. Cetanol 4.0
3. Vaseline 2.0
4). Liquid paraffin 10.0
5. Tocopherol acetate 0.1
6). Vitamin D 0.1
7). Urea 2.0
8). Glycerin 20.0
9. Polyoxyethylene (60) glyceryl isostearate 2.5
10. Glycerol monostearate 1.5
11. Preservative 0.1
12 Perfume appropriate amount13. Purified water remaining
成分２〜６を加熱溶解して混合し、７０℃に保ち油相とする。成分１、７〜１１及び１３を加熱溶解して混合し、７５℃に保ち水相とする。次いで、油相に水相を加えて乳化して、かき混ぜながら冷却し、４５℃で成分１２を加え、さらに３０℃まで冷却して製品とする。 Ingredients 2 to 6 are dissolved by heating and mixed, and kept at 70 ° C. to obtain an oil phase. Ingredients 1, 7 to 11 and 13 are heated and dissolved and mixed, and kept at 75 ° C. to obtain an aqueous phase. Next, the aqueous phase is added to the oil phase to emulsify, and the mixture is cooled while stirring. The component 12 is added at 45 ° C., and further cooled to 30 ° C. to obtain a product.
（処方例９）固形石鹸
処方 配合量(重量％）
１．カガミグサの抽出物 ０．１
２．石鹸素地（＊） ８０．０
３．グリセリン １０．０
４．ソルビトール １．０
５．エデト酸 ０．１
６．酸化チタン ０．１
７、香料 適量
８．精製水 残量
（＊）ラウリン酸ナトリウム、ミリスチン酸ナトリウム、パルミチン酸ナトリウム、ステアリン酸ナトリウム、オレイン酸ナトリウムを含む高級脂肪酸ナトリウム混合物
(Formulation example 9) Solid soap Formulation Blending amount (% by weight)
1. Oyster extract 0.1
2. Soap base (*) 80.0
3. Glycerin 10.0
4). Sorbitol 1.0
5. Edetic acid 0.1
6). Titanium oxide 0.1
7. Perfume appropriate amount 8. Purified water Remaining amount (*) High fatty acid sodium mixture containing sodium laurate, sodium myristate, sodium palmitate, sodium stearate, sodium oleate
全成分を混合して、ミキサー及びローラーで混練し、プロッダーで圧縮することによって棒状の成型物に型打ちし、次いで、成形物を冷却し、乾燥することによって、製品を得る。 All the ingredients are mixed, kneaded with a mixer and a roller, pressed into a rod-shaped molding by compression with a pudder, and then the molding is cooled and dried to obtain a product.
（処方例１０）ボディ用洗浄料
処方 配合量(重量％）
１．カガミグサの抽出物 ０．２
２．ステアリン酸 １０．０
３．パルミチン酸 ８．０
４．ミリスチン酸 １２．０
５．ラウリン酸 ４．０
６．オレイルアルコール １．５
７．精製ラノリン １．０
８．ヤシ油脂肪酸ジエタノールアミド １．０
９．グリセリン １０．０
１０．水酸化カリウム ６．０
１１．香料 適量
１２．防腐剤 適量
１３．金属イオン封鎖剤 適量
１４．精製水 残量
(Prescription Example 10) Body Cleaning Formulation Formulation Amount (% by weight)
1. Ragweed extract 0.2
2. Stearic acid 10.0
3. Palmitic acid 8.0
4). Myristic acid 12.0
5. Lauric acid 4.0
6). Oleyl alcohol 1.5
7). Purified lanolin 1.0
8). Palm oil fatty acid diethanolamide 1.0
9. Glycerin 10.0
10. Potassium hydroxide 6.0
11. Perfume appropriate amount 12. Preservative appropriate amount13. Metal ion sequestering agent Purified water remaining
成分２〜５を加熱溶解して混合し、７０℃に保ち油相とする。成分１４の適量に成分１０を溶解し、油相に添加しケン化を行う。続いて、成分６〜９をケン化物に添加し、室温でさらに成分１、１１〜１３及び残りの成分１４を添加する。 Ingredients 2 to 5 are dissolved by heating and mixed, and kept at 70 ° C. to obtain an oil phase. The component 10 is dissolved in an appropriate amount of the component 14 and added to the oil phase for saponification. Subsequently, components 6 to 9 are added to the saponified product, and components 1, 11 to 13 and the remaining component 14 are further added at room temperature.
（処方例１１）ヘアローション
処方 配合量(重量％）
１．カガミグサの抽出物 ０．２
２．ステアリン酸 ５．０
３．セチルアルコール ５．０
４．流動パラフィン ２．０
５．グリセリンモノステアレート １．３
６．ソルビタンモノオレート １．５
７．ポリオキシエチレン（１０）ソルビタンモノオレート ０．８
８．グリセリン ６．０
９．防腐剤 適量
１０．精製水 残量
(Formulation example 11) Hair lotion Formulation Blending amount (% by weight)
1. Ragweed extract 0.2
2. Stearic acid 5.0
3. Cetyl alcohol 5.0
4). Liquid paraffin 2.0
5. Glycerin monostearate 1.3
6). Sorbitan monooleate 1.5
7). Polyoxyethylene (10) sorbitan monooleate 0.8
8). Glycerin 6.0
9. Preservative appropriate amount10. Purified water remaining
成分２〜７を加熱溶解して混合し、７０℃に保ち油相とした。成分１および８〜１０を加熱溶解して混合し、７５℃に保ち水相とした。油相に水相を加えて乳化し、かき混ぜながら冷却して製品とした。 Ingredients 2-7 were dissolved by heating and mixed, and kept at 70 ° C. to obtain an oil phase. Ingredients 1 and 8 to 10 were dissolved by heating and mixed, and kept at 75 ° C. to obtain an aqueous phase. The aqueous phase was added to the oil phase to emulsify, and the product was cooled with stirring to obtain a product.
（処方例１２）ヘアトニック
処方 配合量(重量％）
１．カガミグサの抽出物 ２．０
２．９５％エタノール ６０．０
３．グリセリン ２．０
４．精製水 残量
(Prescription Example 12) Hair Tonic Formulation Blending amount (% by weight)
1. Oyster extract 2.0
2.95% ethanol 60.0
3. Glycerin 2.0
4). Purified water remaining
成分１を２に溶解し、成分３及び４を加え、十分撹拌混合し、製品とする。 Dissolve component 1 in 2, add components 3 and 4, and mix well with stirring to obtain a product.
（処方例１３）シャンプー
処方 配合量(重量％）
１．カガミグサの抽出物 ０．１
２．アルキル硫酸トリエタノールアミン １８．０
３．ラウリン酸ジエタノールアミド ３．０
４．メチルセルロース ０．５
５．香料 適量
６．精製水 残量
(Formulation Example 13) Shampoo Formulation Blending amount (% by weight)
1. Oyster extract 0.1
2. Alkyl sulfate triethanolamine 18.0
3. Lauric acid diethanolamide 3.0
4). Methylcellulose 0.5
5. Perfume appropriate amount 6. Purified water remaining
成分６に成分４を均一に溶解した後、成分１及び２を加え、７０〜７５℃で加熱溶解した後、成分３を加え、冷却途中に成分５を加え３０℃まで冷却し製品とした。 After component 4 was uniformly dissolved in component 6, components 1 and 2 were added, heated and dissolved at 70 to 75 ° C., component 3 was added, component 5 was added during cooling, and cooled to 30 ° C. to obtain a product.
（処方例１４）浴用剤
処方 配合量(重量％）
１．カガミグサの抽出物 ５．０
２．炭酸水素ナトリウム ５０．０
３．黄色２０２号 適量
４．香料 適量
５．無水硫酸ナトリウム 残量
(Formulation example 14) Bath agent Formulation Formulation amount (% by weight)
1. Oyster extract 5.0
2. Sodium bicarbonate 50.0
3. Yellow 202 No. 4 Perfume appropriate amount 5. Anhydrous sodium sulfate
成分１〜５を均一に混合し製品とする。 Ingredients 1-5 are mixed uniformly to make a product.
（処方例１５）錠剤
処方 配合量(重量％）
１．カガミグサの抽出物 １．０
２．乾燥コーンスターチ ２５．０
３．カルボキシメチルセルロースカルシウム ２０．０
４．微結晶セルロース ４０．０
５．ポリビニルピロリドン ７．０
６．タルク ３．０
(Formulation Example 15) Tablet Formulation Formulation amount (% by weight)
1. Oyster extract 1.0
2. Dried corn starch 25.0
3. Carboxymethylcellulose calcium 20.0
4). Microcrystalline cellulose 40.0
5. Polyvinylpyrrolidone 7.0
6). Talc 3.0
成分１〜５を混合し、次いで１０％の水を結合剤として加えて、押出し造粒後乾燥する。成形した顆粒に成分６を加えて混合し打錠する。１錠０．５２ｇとする。 Components 1-5 are mixed, then 10% water is added as a binder and dried after extrusion granulation. Ingredient 6 is added to the molded granules, mixed and compressed into tablets. One tablet is 0.52 g.
（処方例１６）飲料
処方 配合量(重量％）
１．カガミグサの抽出物 ０．１
２．ステビア ０．０５
３．リンゴ酸 ５．０
４．香料 ０．１
５．精製水 残量
(Formulation Example 16) Beverage Formulation Blending amount (% by weight)
1. Oyster extract 0.1
2. Stevia 0.05
3. Malic acid 5.0
4). Fragrance 0.1
5. Purified water remaining
成分１〜４を成分５の一部の精製水に撹拌溶解する。次いで、成分５の残りの精製水を加えて混合し、９０℃に加熱して５０ｍＬのガラス瓶に充填する。 Components 1 to 4 are dissolved in a part of purified water of component 5 with stirring. The remaining purified water of Component 5 is then added and mixed, heated to 90 ° C. and filled into a 50 mL glass bottle.
本発明は、皮脂分泌の低下が原因となる皮脂欠乏症（乾皮症）や皮脂欠乏性湿疹などの種々の皮膚の障害や損傷の予防、改善、および治療を目的とした医薬品、医薬部外品、化粧品、および飲食品の製造分野において利用できる。 The present invention relates to pharmaceuticals and quasi-drugs for the purpose of prevention, improvement and treatment of various skin disorders and injuries such as sebum deficiency (dry skin disease) and sebum-deficient eczema caused by decreased sebum secretion. It can be used in the field of manufacturing cosmetics and foods and drinks.
Claims (7)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2013269695A JP6341661B2 (en) | 2013-12-26 | 2013-12-26 | Sebum synthesis accelerator |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2013269695A JP6341661B2 (en) | 2013-12-26 | 2013-12-26 | Sebum synthesis accelerator |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015124182A true JP2015124182A (en) | 2015-07-06 |
| JP6341661B2 JP6341661B2 (en) | 2018-06-13 |
Family
ID=53535150
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013269695A Active JP6341661B2 (en) | 2013-12-26 | 2013-12-26 | Sebum synthesis accelerator |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP6341661B2 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021089501A1 (en) * | 2019-11-06 | 2021-05-14 | Dsm Ip Assets B.V. | Novel method |
Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH04134012A (en) * | 1990-09-26 | 1992-05-07 | Sunstar Inc | Sebum secretion promoter |
| JPH0665039A (en) * | 1992-06-05 | 1994-03-08 | Nonogawa Shoji Kk | Cosmetic |
| JPH07109214A (en) * | 1993-06-02 | 1995-04-25 | Nonogawa Shoji Kk | Sebum secretion promoter |
| JP2002212087A (en) * | 2001-01-22 | 2002-07-31 | Kose Corp | Skin care preparation |
| JP2002275080A (en) * | 2001-03-21 | 2002-09-25 | Kose Corp | Skin care preparation |
| WO2007142130A1 (en) * | 2006-06-02 | 2007-12-13 | Heimat Co., Ltd. | Maitake mushroom extract and composition for enhancing the production of sebum comprising the extract |
| JP2008501647A (en) * | 2004-06-04 | 2008-01-24 | 澳美▲製▼▲薬▼▲ツァン▼有限公司 | Application of Ranunculaceae plants and their extracts to pharmaceutical and health care preparations |
| CN102805721A (en) * | 2012-08-01 | 2012-12-05 | 青岛文创科技有限公司 | Traditional Chinese medicine facial mask for skin whitening |
| CN103417750A (en) * | 2013-07-08 | 2013-12-04 | 鲁奎 | Ointment for treating rhagadia and preparation method of same |
-
2013
- 2013-12-26 JP JP2013269695A patent/JP6341661B2/en active Active
Patent Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH04134012A (en) * | 1990-09-26 | 1992-05-07 | Sunstar Inc | Sebum secretion promoter |
| JPH0665039A (en) * | 1992-06-05 | 1994-03-08 | Nonogawa Shoji Kk | Cosmetic |
| JPH07109214A (en) * | 1993-06-02 | 1995-04-25 | Nonogawa Shoji Kk | Sebum secretion promoter |
| JP2002212087A (en) * | 2001-01-22 | 2002-07-31 | Kose Corp | Skin care preparation |
| JP2002275080A (en) * | 2001-03-21 | 2002-09-25 | Kose Corp | Skin care preparation |
| JP2008501647A (en) * | 2004-06-04 | 2008-01-24 | 澳美▲製▼▲薬▼▲ツァン▼有限公司 | Application of Ranunculaceae plants and their extracts to pharmaceutical and health care preparations |
| WO2007142130A1 (en) * | 2006-06-02 | 2007-12-13 | Heimat Co., Ltd. | Maitake mushroom extract and composition for enhancing the production of sebum comprising the extract |
| CN102805721A (en) * | 2012-08-01 | 2012-12-05 | 青岛文创科技有限公司 | Traditional Chinese medicine facial mask for skin whitening |
| CN103417750A (en) * | 2013-07-08 | 2013-12-04 | 鲁奎 | Ointment for treating rhagadia and preparation method of same |
Non-Patent Citations (2)
| Title |
|---|
| 佐藤良夫、鷲尾勝: "皮脂腺に影響を与える２，３因子について", 臨床皮膚科, vol. 21, no. 12, JPN6017031679, 1 November 1967 (1967-11-01), pages 1141 - 1151 * |
| 加藤健: "市場品『白剣』の成分研究", 生薬学雑誌, vol. 第46巻, 第4号, JPN6017036962, 1992, pages 302 - 309 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021089501A1 (en) * | 2019-11-06 | 2021-05-14 | Dsm Ip Assets B.V. | Novel method |
| CN114615969A (en) * | 2019-11-06 | 2022-06-10 | 帝斯曼知识产权资产管理有限公司 | Novel process |
| CN114615969B (en) * | 2019-11-06 | 2024-01-23 | 帝斯曼知识产权资产管理有限公司 | New method |
Also Published As
| Publication number | Publication date |
|---|---|
| JP6341661B2 (en) | 2018-06-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101048166B (en) | Abnormal protein removing composition | |
| CN111053716B (en) | Application of Fuzhuan tea extract in preparation of skin conditioning product | |
| KR101017709B1 (en) | Cosmetic composition comprising the herbal mixed extract comprising panax ginseng c.a meyer showing hair-growth stimulating activity and preventing activity from hair loss | |
| JP2009057325A (en) | Skin-brightening composition and use thereof | |
| JPH10139679A (en) | Isolation inhibitor of chemical mediator, and cosmetic, medicine and food including the same | |
| JPH10120583A (en) | Antiallergic agent, chemical mediator liberation suppressant and antiallergic cosmetic, medicine and food comprising the sam | |
| JP2015124188A (en) | Sebum synthesis inhibitor | |
| JP2016160198A (en) | Kaempferia parviflora-containing compositions | |
| JP2015027998A (en) | Moisturizer, skin barrier function activator, tight junction formation accelerator, trpv4 expression enhancer, intracellular calcium concentration increaser, intracellular calcium concentration increaser, lipid synthesis accelerator, blood flow improver and periocular darkness ameliorator | |
| JP6753602B2 (en) | Proton pump function accelerator | |
| JP6267957B2 (en) | Sebum synthesis inhibitor | |
| KR101964249B1 (en) | Composition for preventing, improving or treating atopic dermatitis comprising mixture of Torilis japonica extract and copper tripeptide-1 as effective component | |
| KR101347910B1 (en) | a Food Composition, a Cosmetic Composition, a Pharmaceutical Composition Comprising Supercritical Fluid Extract of Ginger and Extract of Dropwort Fermented | |
| JP6765090B2 (en) | Black ginger-containing composition | |
| JP6371520B2 (en) | Sebum synthesis accelerator | |
| JP6320034B2 (en) | Sebum synthesis accelerator | |
| JP6341661B2 (en) | Sebum synthesis accelerator | |
| JP2002047193A (en) | Composition for prophylaxis or treatment of allergic dermatitis | |
| JP4421847B2 (en) | Lipolysis accelerator | |
| JP6908265B2 (en) | Apoptosis inhibitor | |
| KR20210123548A (en) | Improvement composition for Hot flash comprising the extract of Salvia miltiorrhiza as an active ingredient | |
| JP2017088538A (en) | Filaggrin production promoter | |
| JP6646408B2 (en) | Ceramide production promoter | |
| JP6587908B2 (en) | Proton pump function promoter | |
| JP2013014627A (en) | Heparin-binding epidermal growth factor-like growth factor (hb-egf) production promoter |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20161014 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20170825 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20171003 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20171120 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20180508 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20180515 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6341661 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |